Rimonabant (Sanofi-Synthelabo)

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 430-435

  Fernandez, Jose R ^a   Allison, David B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; PYRAZOLE DERIVATIVE; RIMONABANT;

ANIMAL; CHEMISTRY; CLINICAL TRIAL; DRUG ANTAGONISM; HUMAN; OBESITY; REVIEW; SMOKING CESSATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; APPETITE DEPRESSANTS; CLINICAL TRIALS; HUMANS; OBESITY; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SMOKING CESSATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3042534848     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. The synthesis and pharmacological evaluation of the cannabinoid antagonist SR 141716A. Dutta AK, Sard H, Ryan W, Razdan RK, Compton DR, Martin BR MED CHEM RES 1994 5 1 54-62
2. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations relevant to future drug discovery and development. Pertwee RG EXPERT OPIN INVESTIG DRUGS 1996 5 10 1245-1253
3. 1) receptors. Arnone M, Muruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G PSYCHOPHARMACOLOGY (BERL ) 1997 132 1 104-106
4. Conformational studies on a diastereoisomeric pair of tricyclic nonclassical cannabinoids by NMR spectroscopy and computer molecular modeling. Xie X, Pavlopoulos S, DiMeglio C, Makriyannis A J MED CHEM 1998 41 2 167-174
5. 1 receptor. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI EUR J PHARMACOL 1997 334 1 R1-R2
6. Information pack - Sanofi-Synthélabo - A brighter future together. Sanofi-Synthélabo COMPANY BROCHURE 1998 December 02
7. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi Carmona M, Casellas P, Ferrara P LIFE SCI 1999 65 6-7 627-635
8. Pharmaceuticals Europe: Sanofi-Synthélabo. LEHMAN BROTHERS INC 1999 October 7
9. Sanofi-Synthélabo financial analysts meeting. Sanofi-Synthélabo COMPANY WORLD WIDE WEB SITE 2000 February 23
10. Sanofi-Synthélabo 2000 results; 58% growth of net profit attributable to the Group and 54% growth of net profit attributable to the Group before non-operating items and goodwill amortization. Sanofi- Synthélabo PRESS RELEASE 2001 February 20
11. 1 receptor recognition and activation. Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Rawan RK, Martin BR J PHARMACOL EXP THER 2001 296 3 1013-1022
12. Financial information: Group presentations - information meeting. Sanofi-Synthélabo COMPANY PRESENTATION 2001 September 3-4
13. American Chemical Society - 222nd National Meeting (Part XIV), Chicago, IL, USA. Rotella D IDDB MEETING REPORT 2001 August 26-30
14. American Chemical Society - 222nd National Meeting (Part XV), Cannabinoids: A tale of use and abuse, Chicago, IL, USA. Brown H IDDB MEETING REPORT 2001 August 26-30
15. 1 receptor antagonist (SR141716A) on feeding and activity in rats. Cullen MJ, Naeve GS, Pelleymounter MA, Schwaebe M, Foster AC ABSTR SOC NEUROSCI 2001 27 805.18
16. Molecular control of adipogenesis and obesity - Keystone Symposium, Keystone, CO, USA. Medvedev A, Robidoux J, Collins S IDDB MEETING REPORT 2002 January 10-16
17. Solvay Pharmaceuticals - a fundamental strategic change for Solvay. Solvay SA COMPANY PRESENTATION 2001 September 14
18. Financial information: Group presentations - information meeting: February 19 & 20, 2002. Sanofi-Synthélabo COMPANY PRESENTATION 2002 February 19-20
19. Sanofi-Synthelabo looks for new type of partnership in Japan. PHARMA JPN 2002 1791 3-4
20. Financial calendar: General meeting of shareholders. Sanofi-Synthélabo COMPANY PRESENTATION 2002 May 22
21. 1 receptor antagonist SR141716 in rats. Croci T, Landi M, Manara L, Rinaldi-Carmona M WORLD CONGR PHARMACOL 2002 24 Abs 70.9
22. World Congress of Pharmacology - XIVth Annual Meeting (Part III) - OVERNIGHT REPORT, San Francisco, CA, USA. Durrance A IDDB MEETING REPORT 2002 July 7-12
23. Digestive Disease Week 2002 (Part VIII), San Francisco, CA, USA. Galligan JJ IDDB MEETING REPORT 2002 May 19-22
24. American Diabetes Association - 62nd Scientific Sessions (Part V), San Francisco, CA, USA. Cawthorne MA IDDB MEETING REPORT 2002
25. World Congress of Pharmacology - XIVth Annual Meeting (Part XIII), Neuropharmacology and Behavioral Pharmacology, San Francisco, CA, USA. Szabadi E IDDB MEETING REPORT 2002 July 7-12
26. Annual report 2001: Sanofi-Synthélabo. Sanofi- Synthélabo ANNUAL REPORT 2002 July 31
27. Financial analysts meeting: Information meeting - September 2 & 3, 2002. Sanofi-Synthélabo COMPANY PRESENTATION 2002 September 2-3
28. New drugs in the R&D pipeline. PHARMA JPN 2002 1815 Extra issue 7
29. Society for Neuroscience - 32nd Annual Meeting (Part VIII) -OVERNIGHT REPORT, Orlando, FL, USA. Cox R IDDB MEETING REPORT 2002 November 2-7
30. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Christopoulos A, Coles P, Lay L, Lew MJ, Angus JA BR J PHARMACOL 2001 132 6 1281-1291
31. Financial analysts meeting: Information meeting - 18 & 19 Febuary, 2003. Sanofi-Synthélabo COMPANY PRESENTATION 2003 February 18-19
32. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Freedland CS, Poston JS, Porino LJ PHARMACOL BIOCHEM BEHAV 2000 67 2 265-270
33. Obesity market overview. Farrigan C, Pang K NAT REV DRUG DISC 2002 1 4 257-258
34. 1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Deroche-Gamonet V, Le Moal M, Piazza PV, Soubrie P PSYCHOPHARMACOLOGY (BERL) 2001 157 3 254-259
35. This week at UMC: UMC receives more than $3 million in January grants and awards. COMPANY WORLD WIDE WEB SITE 2002 February
36. Exane Pharma Seminar, Paris, France: Sanofi-Synthélabo R&D portfolio presentation (May 13, 2003). Sanofi-Synthélabo COMPANY PRESENTATION 2003 May 13
37. Lead discovery: Pharmaceutical development consultants: Novel anorectic strategies. Kirkham TC INTERNET SITE 2001 July
38. London - South Thames Medicines Information Service: Primary care journal watch. INTERNET SITE 2002 September
39. Financial calendar: Information meeting (Paris) - September 2, 2003. Sanofi-Synthélabo COMPANY PRESENTATION 2003 September 02
40. Sanofi chews the fat: Rimonabant anti-obesity NDA to be filed by 2005. FDC REPORTS PINK SHEET 2003 65 37 25-26
41. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Bensaid M, Gary-Bobo M, Esclango A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P MOL PHARMACOL 2003 63 4 908-914
42. 1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Croci T, Landi M, Galzin AM, Marini P BR J PHARMACOL 2003 140 1 115-122
43. Endocannabinoids in the central nervous system - an overview. Fride E PROSTAGLANDINS LEUKOTRIENES ESSENT FATTY ACIDS 2002 66 2-3 221-233
44. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ FEBS LETT 1995 359 2-3 133-136
45. 1 receptors in N1E-115 neuroblastoma cells. Davis MI, Ronesi J, Lovinger DM J BIOL CHEM 2003 278 49 48973-48980
46. Pharmaceuticals - 3Q preview; trends intact, stars aligning. Moore D, Baum A, Mann P, Nieland N ANALYST REPORT 2003 October 09
47. Sanofi-Synthélabo outstanding 2003 performance. Sanofi-Synthélabo PRESS RELEASE 2004 February 16
48. Sanofi-Synthélabo: FY 2003 results ahead of expectations. Harris S, Nowak I, Kocen A UBS 2004 February 17